Lilly in Advanced Talks to Acquire Kelonia for Over $2 Billion—Is a 39x P/E Still Too Rich? Apr 19, 2026 Life Science
No Longer Afraid of Injections, Eli Lilly’s Oral Weight Loss Drug Foundayo Targets a Multibillion-Dollar Market Apr 17, 2026 Life Science
OpenAI Launches Life Science AI Model GPT-Rosalind, Entering Drug Discovery Arena Apr 16, 2026 Life Science, Technology
Overall Weakness in the Healthcare Sector, Why These Two Stocks Are Worth Long-Term Positioning Apr 16, 2026 Life Science
Mirum Pharmaceuticals’ Stock Surged Over 120% in One Year and May Continue to Climb Apr 14, 2026 Life Science
Why Institutions Are Turning Bullish on Biohaven—and the Catalyst That Could Unlock Its Value Apr 13, 2026 Life Science
A Melanoma Drug Successfully Launched, Yet Iovance’s Stock Has Underperformed the Market for Three Years Apr 10, 2026 Life Science
How Should Investors Position Themselves in This Year’s S&P 500 “Dark Horses” Moderna and Target? Apr 9, 2026 Consumer Goods, Life Science
Seeking Opportunities Amid U.S. Stock Market Volatility, These Two Healthcare Stocks Are Both Cheap and High-Yielding Apr 9, 2026 Life Science
Faced with Aggression from Medtronic and Johnson & Johnson, How Does Intuitive Surgical Defend Its Monopoly? Apr 8, 2026 Life Science
Eli Lilly Writes a Check. AC Immune Surges 15%. Is This Strategy or Spare Change? Apr 7, 2026 Life Science
